Continuous treatment with newer agent protects infants against malaria
Long-term treatment with a newer artemisinin-based combination drug for malaria, dihydroartemisinin-piperaquine (DP), substantially and safely reduces the risk of malaria in young children, according to a study funded by the National Institutes of Health (NIH) and published online yesterday in PLoS Medicine.